Atriva Therapeutics’ lead candidate Zapnometinib shows substantial efficacy against SARS-CoV-2

by Paul Lelieveld | Nov 9, 2021 | Meneldor News

New results support the potential of zapnometinib for the treatment of COVID-19 Significant reduction of viral load and pathological signs in vivo Broad antiviral efficacy of zapnometinib against different Coronavirus variants in vitro Tübingen and Frankfurt, Germany,...

Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor

by Paul Lelieveld | Sep 8, 2021 | Meneldor News

NIJMEGEN, the Netherlands, Sept. 08, 2021 (GLOBE NEWSWIRE) — Xenikos B.V., a clinical-stage biopharmaceutical company currently developing a novel therapy for treating immune related disorders, announced today the closing of €40 million in convertible debt...

Spahn/Karliczek: Weiterer Schub zur Entwicklung und Herstellung von versorgungsnahen Arzneimitteln gegen COVID-19

by Paul Lelieveld | Sep 6, 2021 | Meneldor News

Förderung vonArzneimittelkandidatengegenCOVID-19ausder Fördermaßnahme „Klinische Entwicklung von versorgungsnahen COVID-19-Arzneimittelnundderen Herstellungskapazitäten“von BMG und BMBF Das Bundesministerium für Gesundheit(BMG) und das Bundesministerium für...

Xenikos Announces T-Guard® Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives

by Paul Lelieveld | Jul 19, 2021 | Meneldor News

Company Plans to Commence New Pivotal, Randomized Phase 3 Study Evaluating T-Guard®Versus Ruxolitinib in Patients with Grade III or IV Steroid-refractory Acute Graft-Versus-Host Disease in Second Half of 2021 Positive Results Expected to Support Both FDA and EMA...

Byondis Announces Positive Topline Results of Pivotal Phase III TULIP® Study in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

by Paul Lelieveld | Jun 8, 2021 | Uncategorized

Study Meets Primary Endpoint, Confirming the ADC [Vic-]Trastuzumab Duocarmazine (SYD985) is Superior to Physician’s Choice in Delaying Disease Progression June 8 – Byondis B.V. today announced positive topline results from the Phase III TULIP® study, a...